Higher vitamin B6 status is associated with improved survival among patients with stage I-III colorectal cancer. was written by Holowatyj, Andreana N;Ose, Jennifer;Gigic, Biljana;Lin, Tengda;Ulvik, Arve;Geijsen, Anne J M R;Brezina, Stefanie;Kiblawi, Rama;van Roekel, Eline H;Baierl, Andreas;Böhm, Jürgen;Bours, Martijn J L;Brenner, Hermann;Breukink, Stéphanie O;Chang-Claude, Jenny;de Wilt, Johannes H W;Grady, William M;Grünberger, Thomas;Gumpenberger, Tanja;Herpel, Esther;Hoffmeister, Michael;Keulen, Eric T P;Kok, Dieuwertje E;Koole, Janna L;Kosma, Katharina;Kouwenhoven, Ewout A;Kvalheim, Gry;Li, Christopher I;Schirmacher, Peter;Schrotz-King, Petra;Singer, Marie C;van Duijnhoven, Fränzel J B;van Halteren, Henk K;Vickers, Kathy;Vogelaar, F Jeroen;Warby, Christy A;Wesselink, Evertine;Ueland, Per M;Ulrich, Alexis B;Schneider, Martin;Habermann, Nina;Kampman, Ellen;Weijenberg, Matty P;Gsur, Andrea;Ulrich, Cornelia M. And the article was included in The American journal of clinical nutrition in 2022.Related Products of 54-47-7 The following contents are mentioned in the article:
BACKGROUND: Folate-mediated 1-carbon metabolism requires several nutrients, including vitamin B6. Circulating biomarker concentrations indicating high vitamin B6 status are associated with a reduced risk of colorectal cancer (CRC). However, little is known about the effect of B6 status in relation to clinical outcomes in CRC patients. OBJECTIVES: We investigated survival outcomes in relation to vitamin B6 status in prospectively followed CRC patients. METHODS: A total of 2031 patients with stage I-III CRC participated in 6 prospective patient cohorts in the international FOCUS (folate-dependent 1-carbon metabolism in colorectal cancer recurrence and survival) Consortium. Preoperative blood samples were used to measure vitamin B6 status by the direct marker pyridoxal 5′-phosphate (PLP), as well as the functional marker HK-ratio (HKr)[3′-hydroxykynurenine: (kynurenic acid + xanthurenic acid + 3′-hydroxy anthranilic acid + anthranilic acid)]. Using Cox proportional hazards regression, we examined associations of vitamin B6 status with overall survival (OS), disease-free survival (DFS), and risk of recurrence, adjusted for patient age, sex, circulating creatinine concentrations, tumor site, stage, and cohort. RESULTS: After a median follow-up of 3.2 y for OS, higher preoperative vitamin B6 status as assessed by PLP and the functional marker HKr was associated with 16-32% higher all-cause and disease-free survival, although there was no significant association with disease recurrence (doubling in PLP concentration: HROS, 0.68; 95% CI: 0.59, 0.79; HRDFS, 0.84; 95% CI: 0.75, 0.94; HRRecurrence, 0.96; 95% CI: 0.84, 1.09; HKr: HROS, 2.04; 95% CI: 1.67, 2.49; HRDFS, 1.56; 95% CI: 1.31, 1.85; HRRecurrence, 1.21; 95% CI: 0.96,1. 52). The association of PLP with improved OS was consistent across colorectal tumor site (right-sided colon: HROS, 0.75; 95% CI: 0.59, 0.96; left-sided colon: HROS, 0.71; 95% CI: 0.55, 0.92; rectosigmoid junction and rectum: HROS, 0.61; 95% CI: 0.47, 0.78). CONCLUSION: Higher preoperative vitamin B6 status is associated with improved OS among stage I-III CRC patients. This study involved multiple reactions and reactants, such as (4-Formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate (cas: 54-47-7Related Products of 54-47-7).
(4-Formyl-5-hydroxy-6-methylpyridin-3-yl)methyl dihydrogen phosphate (cas: 54-47-7) belongs to pyridine derivatives. In contrast to benzene, Pyridine’s electron density is not evenly distributed over the ring, reflecting the negative inductive effect of the nitrogen atom. One of the examples of pyridines is the well-known alkaloid lithoprimidine, which is an A3 adenosine receptor antagonist and N,N-dimethylaminopyridine (DMAP) analog, commonly used in organic synthesis.Related Products of 54-47-7